Plus Therapeutics (PSTV) Presents Positive ReSPECT-LM Phase 1 Interim Data

Go back to Plus Therapeutics (PSTV) Presents Positive ReSPECT-LM Phase 1 Interim Data

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

December 17, 2024 7:30 AM EST

Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation

Both single-dose and multiple-dose expansion trials planned in 2025

AUSTIN, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) --... More